Compare Abercrombie & Fitch Co. (ANF) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abercrombie & Fitch Co. vs DexCom, Inc. — how do they compare? Abercrombie & Fitch Co. trades at $114.14 (market cap $5.24B), while DexCom, Inc. trades at $90.12 (market cap $33.79B). The key difference: DexCom, Inc. is far larger — about 6.4× Abercrombie & Fitch Co.'s market cap, and DexCom, Inc. is trading nearer its 52-week high, Abercrombie & Fitch Co. nearer its low. Which is the better fit depends on your goals.
| ANF | DXCM | |
|---|---|---|
Market Cap | $5.24B | $33.79B |
Sector | Consumer Cyclical | Health |
52-Week High | $129.85 | $89.53 |
52-Week Low | $65.61 | $54.84 |
Enterprise Value | $5.91B | $33.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ANF trades at $118.53, up 5.25% today, reflecting strong momentum. The stock exhibits bullish technical signals with support at $114 and resistance at $121. Fundamentally, the company reported robust earnings, with Q1 2026 EPS of $1.47 beating expectations of $1.28, and revenue growth from $4.3B in 2024 to $4.95B in 2025. Profitability metrics are solid, with a net income margin of 11.44% in 2025 and ROE of 39.04%.
Outlook is positive due to consistent earnings beats and strategic campaigns, but risks include market volatility and competitive pressures. Analysts are mixed with a consensus price target of $112.86, below the current price, suggesting potential overvaluation. Institutional interest is growing, with Amundi increasing its stake by 201.2% in Q2 2026.
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abercrombie & Fitch Co.
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Read more on ANF →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
